<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00413244</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 06-1081</org_study_id>
    <nct_id>NCT00413244</nct_id>
  </id_info>
  <brief_title>The Cardiac Benefit of Testosterone Replacement in Men With Low Testosterone Levels With Coronary Artery Disease After Successful Intervention of the Blockage or Narrowed Heart Artery</brief_title>
  <official_title>The Cardiac Benefit of Androgen Replacement in Hypogonadal Males With Coronary Artery Disease Following Successful Percutaneous Coronary Intervention (PCI).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to find out if giving the study drug, Androgel (testosterone) as
      a testosterone replacement help bring the testosterone to an acceptable level and to find out
      if it will help improve heart condition in males with coronary artery disease (CAD) following
      successful percutaneous coronary intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Males with coronary heart disease have lower serum levels of bioavailable testosterone than
      men of a similar age with normal coronary angiograms (English, European Heart Journal, 2000).
      Low plasma testosterone has been associated with known risk factors for CHD, including age,
      obesity, hyperinsulinemia, diabetes, and adverse lipid profile.

      Testosterone has also been shown in numerous studies to be a vasodilator. Recently,
      testosterone replacement compared with placebo, in hypogonadal men was shown to improve time
      to ischemic threshold, assessed by treadmill exercise testing at 4 and 12 weeks (Malkin,
      Heart, 2000). Prior studies had also shown a beneficial effect on exercise-induced ischemia
      in men with CAD, but not exclusively hypogonadal men (Jaffe,Br Heart J 1977; Rosano,
      Circulation, 1999; English, Circulation, 2000). In addition, this proposed study would be the
      first study to assess if the anti-anginal effects persists long term.

      This is a randomized, double-blind, placebo-controlled study to evaluate the safety and
      efficacy of testosterone supplementation in hypogonadal men with coronary artery disease
      following successful revascularization with percutaneous coronary intervention (PCI). Only
      those men who had successful coronary artery revascularization, and on stable cardiac medical
      regimen for the prior 4 weeks will be included. Eligible patients will then be randomized on
      a 2:1 basis with 50 subjects receiving 5 grams of AndroGel and 25 subjects receiving placebo
      gel.

      The men in this study who demonstrate hypogonadism represent a novel population to
      demonstrate the safety and efficacy of testosterone supplementation to improve cardiac
      function and outcomes. We hypothesize that treatment of hypogonadism in men with CAD,
      following successful PCI, will significantly improve cardiac ischemic threshold as assessed
      by cardiac stress testing. Furthermore, additional cardiac endpoints such as angina status,
      endothelial function and inflammatory serum markers will also demonstrate significant benefit
      in the testosterone treated group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac Stress Test: Time to ST Depression</measure>
    <time_frame>at 6 months</time_frame>
    <description>Treadmill exercise testing performed according to the Bruce protocol (MAX-1 Marquette advanced exercise system, software version 002E). The system analyzed the signal averaged ECG and produces a graphical display of the level of the ST segment 80 ms after the J point against time. Time to 1 mm ST depression was measured from computer derived analysis, effectively eliminating observer bias.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac Stress Testing: Exercise Capacity</measure>
    <time_frame>At 1 month, 3 months, and 6 months</time_frame>
    <description>Exercise capacity was measured using exercise time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seattle Angina Questionnaire (SAQ)</measure>
    <time_frame>up to 6 months</time_frame>
    <description>A cardiac disease-related quality-of-life measure. The SAQ is a self-report instrument with 19 items that, yields five subscale scores: physical limitation, angina stability, angina frequency, treatment satisfaction, and disease perception. The possible range of scores for each of the five subscales is 0 to 100, with higher scores indicating better quality of life. A change of 10 points in any of the subscales is considered to be clinically important.
Data not collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reactive Hyperemia Index</measure>
    <time_frame>6 months</time_frame>
    <description>The Reactive Hyperemia Index measures the endothelial function and predicts future coronary events. In general RHI values below 2 are categorized as endothelial dysfunction and have a greater plaque burden, whereas higher RHI values are considered normal or improved endothelial function. PAT is the technique to non-invasively assess endothelial function. It comprises finger probes to evaluate digital volume changes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Prostate Symptom Score (IPSS)</measure>
    <time_frame>6 months</time_frame>
    <description>IPSS has 7 questions related to symptoms, each item scored 1-5. Total score can range from 0 to 35 (asymptomatic to very symptomatic). The 8th question refers to the patient's perceived quality of life ranged from 0 to 6 (&quot;delighted&quot; to &quot;terrible&quot;.) Data not collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic Equivalents of Task (METS)</measure>
    <time_frame>6 months</time_frame>
    <description>The Metabolic Equivalent of Task (MET), or simply metabolic equivalent, is a physiological measure expressing the energy cost of physical activities and is defined as the ratio of metabolic rate (and therefore the rate of energy consumption) during a specific physical activity to a reference metabolic rate, set by convention to 3.5 ml O2·kg−1·min−1 or equivalently</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aging Male Symptoms (AMS)</measure>
    <time_frame>At baseline, 1 month, 3 months, and 6 months</time_frame>
    <description>The scale assesses symptoms of aging and their impact on HRQoL in males, and increases with increasing severity (1 to 5) of subjectively perceived complaints in 17 items. Scale ranges from 17-85 (no symptoms to extremely severe symptoms.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Index of Erectile Function (IIEF)</measure>
    <time_frame>At baseline, 1 month, 3 months, and 6 months</time_frame>
    <description>Questions 1-5 15 of the IIEF relates to erectile function scale 0 - 30 (severe erectile dysfunction to no erectile dysfunction).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IIEF-II Orgasmic Function</measure>
    <time_frame>At baseline, 1 month, 3 months, and 6 months</time_frame>
    <description>Questions 9-10 of the IIEF relates to orgasmic function scale 0 - 10 (from no impairment to severe impairment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IIEF -III: Sexual Desire</measure>
    <time_frame>At baseline, 1 month, 3 months, and 6 months</time_frame>
    <description>Questions 11-12 of the IIEF relates to sexual desire scale 0-10 (from very low to very high)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IIEF-IV: Intercourse Satisfaction</measure>
    <time_frame>At baseline, 1 month, 3 months, and 6 months</time_frame>
    <description>Questions 6,7, 8 of the IIEF relates to intercourse satisfaction scale 0 - 15 (from very dissatisfied to very satisfied)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IIEF-V: Over-all Satisfaction</measure>
    <time_frame>At baseline, 1 month, 3 months, and 6 months</time_frame>
    <description>Questions 13,14 of the IIEF relates to specifically to overall satisfaction scale from 0 - 10 (very dissatisfied to very satisfied)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Androgel treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Androgel 5 grams
Androgel treatment - subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo - will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AndroGel 5 Grams</intervention_name>
    <description>Placebo (randomization will occur on a 2:1 drug to placebo). A total of 50 subjects will be randomized to receive Androgel 5 grams and 25 subjects will be randomized to receive placebo.
Androgel treatment/Placebo (after the treatment arm is assigned, subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months.</description>
    <arm_group_label>Androgel treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (randomization will occur on a 2:1 drug to placebo). A total of 50 subjects will be randomized to receive Androgel 5 grams and 25 subjects will be randomized to receive placebo.
Androgel treatment/Placebo (after the treatment arm is assigned, subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult male patients with coronary artery disease (CAD) (one to three vessel diseased).

          -  Stable cardiac status at least 3 months after percutaneous coronary intervention
             (PCI).

          -  No change in cardiac medications for 4 weeks prior to enrollment.

          -  Testosterone &lt; 300 ng/dl or free testosterone &lt; 5.0 ng/dl or bioavailable testosterone
             &lt; 150 ng/dl.

          -  Sex Hormone Binding Globulin (SHBG) &lt; 7nmol/liter and Free Testosterone &lt; 50pg/dl

          -  Prostate Specific Antigen (PSA) &lt; 2.5 ng/mL or 2.6-3.7ng/mL with a negative prostate
             biopsy within the last 6 months and pathology report available for investigator's
             review.

          -  Subgroup of diabetics with well to moderately controlled diabetes (defined by a HgbA1c
             of &lt; 9mg/dL.

        Exclusion Criteria:

          -  Hematocrit greater than 50%.

          -  Severe hypertension (exhibit systolic blood pressure &gt;180mmHg and diastolic blood
             pressure &gt;110 mmHg at baseline visit or a have a history of malignant hypertension.

          -  Significant cardiac arrhythmia (supraventricular tachycardia [SVT] or ventricular
             tachycardia with heart rate exceeding 110 beats per minute at Visit 1).

          -  ECG abnormalities precluding ST segment analysis on treadmill, or inability to walk on
             treadmill.

          -  Poorly controlled, symptomatic, active medical problems (HIV, hepatitis, cancer,
             benign prostatic hypertrophy, alcohol or drug abuse, major depressive disorder).

          -  Neurological or psychiatric disorder that would compromise the patient's ability to
             give informed consent or adhere to the requirements of the protocol.

          -  History of prostate cancer

          -  History of hypersensitivity to transdermal testosterone gel.

          -  International Prostate Symptom Score (IPSS) &gt;19 at Visit 1.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Ann McLaughlin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2006</study_first_submitted>
  <study_first_submitted_qc>December 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2006</study_first_posted>
  <results_first_submitted>May 25, 2016</results_first_submitted>
  <results_first_submitted_qc>November 7, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 5, 2017</results_first_posted>
  <last_update_submitted>November 7, 2016</last_update_submitted>
  <last_update_submitted_qc>November 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypogonadal</keyword>
  <keyword>coronary artery disease</keyword>
  <keyword>percutaneous coronary intervention (PCI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects recruited for the study were male patients with stable cardiac status at least 3 months after Percutaneous Coronary Intervention (PCI) at the Cardiac Catheterization Lab of Mount Sinai Hospital from July 2007 to August 2013.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Androgel</title>
          <description>Androgel 5 grams</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matching Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Androgel</title>
          <description>Androgel 5 grams</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matching Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="51"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.3" spread="8.2"/>
                    <measurement group_id="B2" value="58.9" spread="7.3"/>
                    <measurement group_id="B3" value="58.5" spread="7.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.8" spread="5.8"/>
                    <measurement group_id="B2" value="28.0" spread="4.3"/>
                    <measurement group_id="B3" value="29.7" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Testosterone</title>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="246.7" spread="63.5"/>
                    <measurement group_id="B2" value="263.7" spread="71.9"/>
                    <measurement group_id="B3" value="253.36" spread="66.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123.81" spread="13.81"/>
                    <measurement group_id="B2" value="128.05" spread="20.84"/>
                    <measurement group_id="B3" value="125.47" spread="16.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.32" spread="9.03"/>
                    <measurement group_id="B2" value="75.10" spread="11.65"/>
                    <measurement group_id="B3" value="75.84" spread="10.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hematocrit</title>
          <units>percent of cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.69" spread="3.00"/>
                    <measurement group_id="B2" value="40.93" spread="3.18"/>
                    <measurement group_id="B3" value="40.78" spread="3.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>White Blood Cell Count</title>
          <units>cells x10^3/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.25" spread="1.78"/>
                    <measurement group_id="B2" value="6.49" spread="1.63"/>
                    <measurement group_id="B3" value="6.34" spread="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Red Blood Cell Count</title>
          <units>cells x10^6/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.58" spread="0.44"/>
                    <measurement group_id="B2" value="4.67" spread="0.42"/>
                    <measurement group_id="B3" value="4.62" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Aging male syndrome questionnaire</title>
          <description>The scale assesses symptoms of aging and their impact on HRQoL in males, and increases with increasing severity (1 to 5) of subjectively perceived complaints in 17 items. Scale ranges from 17-85 (no symptoms to extremely severe symptoms.)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.48" spread="11.36"/>
                    <measurement group_id="B2" value="35.85" spread="10.24"/>
                    <measurement group_id="B3" value="36.24" spread="10.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Exercise Time</title>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="507.29" spread="153.48"/>
                    <measurement group_id="B2" value="530.00" spread="120.08"/>
                    <measurement group_id="B3" value="516.20" spread="104.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>International Prostate Symptom Score (IPSS)</title>
          <description>IPSS has 8 questions total - 7 questions related to symptoms, each item scored 1-5. (asymptomatic to very symptomatic). The 8th question refers to the patient's perceived quality of life ranged from 0 to 6 (&quot;delighted&quot; to &quot;terrible&quot;.) Total scale ranges from 8-35. Mild (symptom score less than of equal to 7) Moderate (symptom score range 8-19) Severe (symptom score range 20-35)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.68" spread="4.77"/>
                    <measurement group_id="B2" value="4.55" spread="4.7"/>
                    <measurement group_id="B3" value="5.24" spread="4.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Metabolic equivalent of task (METs)</title>
          <units>MET units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.03" spread="2.58"/>
                    <measurement group_id="B2" value="10.05" spread="1.99"/>
                    <measurement group_id="B3" value="10.04" spread="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Reactive hyperemia index (RHI)</title>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.97" spread="0.72"/>
                    <measurement group_id="B2" value="1.85" spread="0.54"/>
                    <measurement group_id="B3" value="1.92" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Cholesterol</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="157.29" spread="47.10"/>
                    <measurement group_id="B2" value="144.45" spread="28.85"/>
                    <measurement group_id="B3" value="152.25" spread="41.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LDL</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86.48" spread="40.52"/>
                    <measurement group_id="B2" value="80.90" spread="26.77"/>
                    <measurement group_id="B3" value="84.29" spread="35.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142.23" spread="100.95"/>
                    <measurement group_id="B2" value="109.90" spread="50.86"/>
                    <measurement group_id="B3" value="129.55" spread="85.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist Circumference</title>
          <units>inches</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.66" spread="5.21"/>
                    <measurement group_id="B2" value="41.31" spread="4.65"/>
                    <measurement group_id="B3" value="42.13" spread="4.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>lbs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="205.73" spread="39.22"/>
                    <measurement group_id="B2" value="194.50" spread="36.62"/>
                    <measurement group_id="B3" value="201.32" spread="38.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cardiac Stress Test: Time to ST Depression</title>
        <description>Treadmill exercise testing performed according to the Bruce protocol (MAX-1 Marquette advanced exercise system, software version 002E). The system analyzed the signal averaged ECG and produces a graphical display of the level of the ST segment 80 ms after the J point against time. Time to 1 mm ST depression was measured from computer derived analysis, effectively eliminating observer bias.</description>
        <time_frame>at 6 months</time_frame>
        <population>Subjects analyzed were only those subjects with ST depression at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Androgel</title>
            <description>Androgel 5 grams</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Stress Test: Time to ST Depression</title>
          <description>Treadmill exercise testing performed according to the Bruce protocol (MAX-1 Marquette advanced exercise system, software version 002E). The system analyzed the signal averaged ECG and produces a graphical display of the level of the ST segment 80 ms after the J point against time. Time to 1 mm ST depression was measured from computer derived analysis, effectively eliminating observer bias.</description>
          <population>Subjects analyzed were only those subjects with ST depression at baseline</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="439.1" spread="205.2"/>
                    <measurement group_id="O2" value="279.5" spread="130.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="364.0" spread="141.4"/>
                    <measurement group_id="O2" value="292.6" spread="63.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="433.0" spread="123.2"/>
                    <measurement group_id="O2" value="342.2" spread="62.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistician used all the time points post-baseline together (“Overall”). The result gives the estimates and 95% CI of the treatment effect from longitudinal analyses (generalized estimating equation method) which basically pools data from all visits post-baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>log mean</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cardiac Stress Testing: Exercise Capacity</title>
        <description>Exercise capacity was measured using exercise time.</description>
        <time_frame>At 1 month, 3 months, and 6 months</time_frame>
        <population>Subjects analyzed were only those subjects with ST depression at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Androgel</title>
            <description>Androgel 5 grams</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Stress Testing: Exercise Capacity</title>
          <description>Exercise capacity was measured using exercise time.</description>
          <population>Subjects analyzed were only those subjects with ST depression at baseline</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="589.7" spread="114.6"/>
                    <measurement group_id="O2" value="452.4" spread="122.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="607.6" spread="152.0"/>
                    <measurement group_id="O2" value="472.1" spread="98.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="614.0" spread="115.4"/>
                    <measurement group_id="O2" value="470.0" spread="143.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seattle Angina Questionnaire (SAQ)</title>
        <description>A cardiac disease-related quality-of-life measure. The SAQ is a self-report instrument with 19 items that, yields five subscale scores: physical limitation, angina stability, angina frequency, treatment satisfaction, and disease perception. The possible range of scores for each of the five subscales is 0 to 100, with higher scores indicating better quality of life. A change of 10 points in any of the subscales is considered to be clinically important.
Data not collected.</description>
        <time_frame>up to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Androgel</title>
            <description>Androgel 5 grams</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Seattle Angina Questionnaire (SAQ)</title>
          <description>A cardiac disease-related quality-of-life measure. The SAQ is a self-report instrument with 19 items that, yields five subscale scores: physical limitation, angina stability, angina frequency, treatment satisfaction, and disease perception. The possible range of scores for each of the five subscales is 0 to 100, with higher scores indicating better quality of life. A change of 10 points in any of the subscales is considered to be clinically important.
Data not collected.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reactive Hyperemia Index</title>
        <description>The Reactive Hyperemia Index measures the endothelial function and predicts future coronary events. In general RHI values below 2 are categorized as endothelial dysfunction and have a greater plaque burden, whereas higher RHI values are considered normal or improved endothelial function. PAT is the technique to non-invasively assess endothelial function. It comprises finger probes to evaluate digital volume changes.</description>
        <time_frame>6 months</time_frame>
        <population>Subjects analyzed were only those subjects with ST depression at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Androgel</title>
            <description>Androgel 5 grams</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Reactive Hyperemia Index</title>
          <description>The Reactive Hyperemia Index measures the endothelial function and predicts future coronary events. In general RHI values below 2 are categorized as endothelial dysfunction and have a greater plaque burden, whereas higher RHI values are considered normal or improved endothelial function. PAT is the technique to non-invasively assess endothelial function. It comprises finger probes to evaluate digital volume changes.</description>
          <population>Subjects analyzed were only those subjects with ST depression at baseline</population>
          <units>mls</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" spread="0.72"/>
                    <measurement group_id="O2" value="1.85" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.85" spread="0.49"/>
                    <measurement group_id="O2" value="1.81" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.70" spread="0.49"/>
                    <measurement group_id="O2" value="1.77" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 6 moths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="0.58"/>
                    <measurement group_id="O2" value="1.74" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>International Prostate Symptom Score (IPSS)</title>
        <description>IPSS has 7 questions related to symptoms, each item scored 1-5. Total score can range from 0 to 35 (asymptomatic to very symptomatic). The 8th question refers to the patient's perceived quality of life ranged from 0 to 6 (&quot;delighted&quot; to &quot;terrible&quot;.) Data not collected.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Androgel</title>
            <description>Androgel 5 grams</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>International Prostate Symptom Score (IPSS)</title>
          <description>IPSS has 7 questions related to symptoms, each item scored 1-5. Total score can range from 0 to 35 (asymptomatic to very symptomatic). The 8th question refers to the patient's perceived quality of life ranged from 0 to 6 (&quot;delighted&quot; to &quot;terrible&quot;.) Data not collected.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metabolic Equivalents of Task (METS)</title>
        <description>The Metabolic Equivalent of Task (MET), or simply metabolic equivalent, is a physiological measure expressing the energy cost of physical activities and is defined as the ratio of metabolic rate (and therefore the rate of energy consumption) during a specific physical activity to a reference metabolic rate, set by convention to 3.5 ml O2·kg−1·min−1 or equivalently</description>
        <time_frame>6 months</time_frame>
        <population>Subjects analyzed were only those subjects with ST depression at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Androgel</title>
            <description>Androgel 5 grams</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolic Equivalents of Task (METS)</title>
          <description>The Metabolic Equivalent of Task (MET), or simply metabolic equivalent, is a physiological measure expressing the energy cost of physical activities and is defined as the ratio of metabolic rate (and therefore the rate of energy consumption) during a specific physical activity to a reference metabolic rate, set by convention to 3.5 ml O2·kg−1·min−1 or equivalently</description>
          <population>Subjects analyzed were only those subjects with ST depression at baseline</population>
          <units>METS units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" spread="2.2"/>
                    <measurement group_id="O2" value="9.0" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" spread="2.2"/>
                    <measurement group_id="O2" value="9.0" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" spread="3.0"/>
                    <measurement group_id="O2" value="9.2" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" spread="2.2"/>
                    <measurement group_id="O2" value="9.4" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aging Male Symptoms (AMS)</title>
        <description>The scale assesses symptoms of aging and their impact on HRQoL in males, and increases with increasing severity (1 to 5) of subjectively perceived complaints in 17 items. Scale ranges from 17-85 (no symptoms to extremely severe symptoms.)</description>
        <time_frame>At baseline, 1 month, 3 months, and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Androgel</title>
            <description>Androgel 5 grams</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Aging Male Symptoms (AMS)</title>
          <description>The scale assesses symptoms of aging and their impact on HRQoL in males, and increases with increasing severity (1 to 5) of subjectively perceived complaints in 17 items. Scale ranges from 17-85 (no symptoms to extremely severe symptoms.)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5" spread="11.4"/>
                    <measurement group_id="O2" value="35.8" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.9" spread="10.1"/>
                    <measurement group_id="O2" value="29.8" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5" spread="11.4"/>
                    <measurement group_id="O2" value="35.9" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.2" spread="8.5"/>
                    <measurement group_id="O2" value="31.4" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>International Index of Erectile Function (IIEF)</title>
        <description>Questions 1-5 15 of the IIEF relates to erectile function scale 0 - 30 (severe erectile dysfunction to no erectile dysfunction).</description>
        <time_frame>At baseline, 1 month, 3 months, and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Androgel</title>
            <description>Androgel 5 grams</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>International Index of Erectile Function (IIEF)</title>
          <description>Questions 1-5 15 of the IIEF relates to erectile function scale 0 - 30 (severe erectile dysfunction to no erectile dysfunction).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" spread="8.7"/>
                    <measurement group_id="O2" value="12.2" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" spread="9.0"/>
                    <measurement group_id="O2" value="10.1" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" spread="9.6"/>
                    <measurement group_id="O2" value="14.2" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" spread="10.0"/>
                    <measurement group_id="O2" value="12.5" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IIEF-II Orgasmic Function</title>
        <description>Questions 9-10 of the IIEF relates to orgasmic function scale 0 - 10 (from no impairment to severe impairment)</description>
        <time_frame>At baseline, 1 month, 3 months, and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Androgel</title>
            <description>Androgel 5 grams</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>IIEF-II Orgasmic Function</title>
          <description>Questions 9-10 of the IIEF relates to orgasmic function scale 0 - 10 (from no impairment to severe impairment)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="3.3"/>
                    <measurement group_id="O2" value="4.4" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="3.5"/>
                    <measurement group_id="O2" value="4.2" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="3.7"/>
                    <measurement group_id="O2" value="5.8" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="3.4"/>
                    <measurement group_id="O2" value="5.5" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IIEF -III: Sexual Desire</title>
        <description>Questions 11-12 of the IIEF relates to sexual desire scale 0-10 (from very low to very high)</description>
        <time_frame>At baseline, 1 month, 3 months, and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Androgel</title>
            <description>Androgel 5 grams</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>IIEF -III: Sexual Desire</title>
          <description>Questions 11-12 of the IIEF relates to sexual desire scale 0-10 (from very low to very high)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="2.1"/>
                    <measurement group_id="O2" value="5.4" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="2.7"/>
                    <measurement group_id="O2" value="4.8" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="2.3"/>
                    <measurement group_id="O2" value="5.6" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="2.4"/>
                    <measurement group_id="O2" value="5.5" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IIEF-IV: Intercourse Satisfaction</title>
        <description>Questions 6,7, 8 of the IIEF relates to intercourse satisfaction scale 0 - 15 (from very dissatisfied to very satisfied)</description>
        <time_frame>At baseline, 1 month, 3 months, and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Androgel</title>
            <description>Androgel 5 grams</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>IIEF-IV: Intercourse Satisfaction</title>
          <description>Questions 6,7, 8 of the IIEF relates to intercourse satisfaction scale 0 - 15 (from very dissatisfied to very satisfied)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="4.0"/>
                    <measurement group_id="O2" value="5.0" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="4.6"/>
                    <measurement group_id="O2" value="3.6" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="4.9"/>
                    <measurement group_id="O2" value="6.0" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="5.1"/>
                    <measurement group_id="O2" value="5.2" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IIEF-V: Over-all Satisfaction</title>
        <description>Questions 13,14 of the IIEF relates to specifically to overall satisfaction scale from 0 - 10 (very dissatisfied to very satisfied)</description>
        <time_frame>At baseline, 1 month, 3 months, and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Androgel</title>
            <description>Androgel 5 grams</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>IIEF-V: Over-all Satisfaction</title>
          <description>Questions 13,14 of the IIEF relates to specifically to overall satisfaction scale from 0 - 10 (very dissatisfied to very satisfied)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="2.5"/>
                    <measurement group_id="O2" value="4.3" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="2.9"/>
                    <measurement group_id="O2" value="3.8" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="2.9"/>
                    <measurement group_id="O2" value="5.2" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="3.0"/>
                    <measurement group_id="O2" value="4.9" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Androgel</title>
          <description>Androgel 5 grams</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matching Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mary Ann McLaughlin</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>(212) 241-3340</phone>
      <email>maryann.mclaughlin@mountsinai.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

